Emerging Cell-Based Gene Therapies in Sickle Cell Disease: A Systematic Review of Casgevy and Lyfgenia
Background: In 2023, the FDA approved two emerging cell-based gene therapies for the treatment of severe sickle cell disease (SCD): Casgevy and Lyfgenia. Casgevy utilizes the newer CRISPR/Cas9 technology, while Lyfgenia relies on a Lentiviral vector. These therapies consist of autologous hematopoiet...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Medical Research and Development Corporation
2024-09-01
|
| Series: | International Journal of Biomedicine |
| Subjects: | |
| Online Access: | http://www.ijbm.org/articles/i55/ijbm_14(3)_ra2.pdf |